The Silicon Review ^Asia

AI Medical Service Inc. (AMS), which is termed as areal-time endoscopic AI developer based in Tokyo, has raised approximately around US$42.9 million in series B funding from various sectors like Globis Capital Partners, World Innovation Lab, and Sony Innovation Fund, as well as additional third-party allocations.

AMS intends to use the new funds to promote clinical trials, clinical safety equipment’s to further develop its pipeline, hire expert personnel, and invest in equipment and overseas expansion.By this move it will help to develop its technology, the company hopes to accelerate regulatory approval and contribute to the development of endoscopic medical care worldwide.

The company was founded on the desire to solve issues with endoscopies in the clinics and the firm mainly focuses on AI in esophageal cancer, colorectal cancer, and capsule endoscopy AI. “In order to commercialize and deliver the AI products to society as soon as possible, we will make effective use of the procured funds,” Tomohiro Tada, CEO of AMS, said.

AMS develops AI technology that leverages the wisdom of Japanese endoscopic specialists and supports endoscopic examinations of gastrointestinal organs. The firm is all set to collaborate with around 80 medical institutions worldwide, representing Japan in the field of research and development of AI endoscopies which will be the first of its kind in Asia.